These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 26966027)

  • 1. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
    Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A
    J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study.
    Ono A; Murakami H; Seto T; Shimizu T; Watanabe S; Takeshita S; Takeda K; Toyoshima J; Nagase I; Bahceci E; Morishita M; Morita S; Fukuoka M; Nakagawa K
    Drugs R D; 2021 Mar; 21(1):65-78. PubMed ID: 33331996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.
    Nishio M; Murakami H; Horiike A; Takahashi T; Hirai F; Suenaga N; Tajima T; Tokushige K; Ishii M; Boral A; Robson M; Seto T
    J Thorac Oncol; 2015 Jul; 10(7):1058-66. PubMed ID: 26020125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
    Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceritinib in ALK-rearranged non-small-cell lung cancer.
    Shaw AT; Kim DW; Mehra R; Tan DS; Felip E; Chow LQ; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Lau YY; Goldwasser M; Boral AL; Engelman JA
    N Engl J Med; 2014 Mar; 370(13):1189-97. PubMed ID: 24670165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
    Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
    Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
    Horn L; Infante JR; Reckamp KL; Blumenschein GR; Leal TA; Waqar SN; Gitlitz BJ; Sanborn RE; Whisenant JG; Du L; Neal JW; Gockerman JP; Dukart G; Harrow K; Liang C; Gibbons JJ; Holzhausen A; Lovly CM; Wakelee HA
    Clin Cancer Res; 2018 Jun; 24(12):2771-2779. PubMed ID: 29563138
    [No Abstract]   [Full Text] [Related]  

  • 10. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
    Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
    Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
    Kim DW; Mehra R; Tan DSW; Felip E; Chow LQM; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT
    Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
    Shaw AT; Gandhi L; Gadgeel S; Riely GJ; Cetnar J; West H; Camidge DR; Socinski MA; Chiappori A; Mekhail T; Chao BH; Borghaei H; Gold KA; Zeaiter A; Bordogna W; Balas B; Puig O; Henschel V; Ou SI;
    Lancet Oncol; 2016 Feb; 17(2):234-242. PubMed ID: 26708155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
    Camidge DR; Bang YJ; Kwak EL; Iafrate AJ; Varella-Garcia M; Fox SB; Riely GJ; Solomon B; Ou SH; Kim DW; Salgia R; Fidias P; Engelman JA; Gandhi L; Jänne PA; Costa DB; Shapiro GI; Lorusso P; Ruffner K; Stephenson P; Tang Y; Wilner K; Clark JW; Shaw AT
    Lancet Oncol; 2012 Oct; 13(10):1011-9. PubMed ID: 22954507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study.
    Xing P; Zhao Q; Zhang L; Wang H; Huang D; Hu P; Sun Y; Shi Y
    BMC Med; 2022 Nov; 20(1):453. PubMed ID: 36424628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset.
    Hida T; Satouchi M; Nakagawa K; Seto T; Matsumoto S; Kiura K; Nokihara H; Murakami H; Tokushige K; Hatano B; Nishio M
    Jpn J Clin Oncol; 2017 Jul; 47(7):618-624. PubMed ID: 28369553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
    Solomon BJ; Mok T; Kim DW; Wu YL; Nakagawa K; Mekhail T; Felip E; Cappuzzo F; Paolini J; Usari T; Iyer S; Reisman A; Wilner KD; Tursi J; Blackhall F;
    N Engl J Med; 2014 Dec; 371(23):2167-77. PubMed ID: 25470694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
    Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
    Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.
    Fischer M; Moreno L; Ziegler DS; Marshall LV; Zwaan CM; Irwin MS; Casanova M; Sabado C; Wulff B; Stegert M; Wang L; Hurtado FK; Branle F; Geoerger B; Schulte JH
    Lancet Oncol; 2021 Dec; 22(12):1764-1776. PubMed ID: 34780709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.